Maynard Um
-
-
-
-
-
-
-
Moonlake Immunotherapeutics (MLTX) PT Raised to $45 at Clear Street
-
-
-
-
-
-
-
H.C. Wainwright Downgrades Moonlake Immunotherapeutics (MLTX) to Neutral
-
-
-
-
-
-
-
Wedbush Reiterates Outperform Rating on Moonlake Immunotherapeutics (MLTX)
-
-
-
-
-
-
-
MoonLake Immunotherapeutics (MLTX) Misses Q2 EPS by 15c
-
-
-
-
-
-
-
Merck (MRK) Held Talks To Buy MoonLake Immunotherapeutics (MLTX) - FT
-
-
-
-
-
-
-
Guggenheim Reiterates Buy Rating on Moonlake Immunotherapeutics (MLTX), Top Pick
-
-
-
-
-
-
-
Wolfe Research Downgrades Moonlake Immunotherapeutics (MLTX) to Peerperform
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

